Press Releases

Part A of TYDAL-TIMI 78 Trial met all objectives, with statistically significant placebo-adjusted triglyceride reductions of 39.1%–45.5% across all three doses at Week 12 and up to 57.2% in participants with baseline triglycerides ≥300 mg/dL Reductions from baseline of up to 72.2% in participants

SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop

Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee LIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today

LIBERTY CORNER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company, today announced that the United States Patent and Trademark Office (“USPTO”) has granted a new Method of Use patent for certepetide

Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, compared to the daily subcutaneous injections required by the current standard of care By directly

Late-breaking presentation will highlight Phase 2b clinical data for MAR001, a potential first-in-class antibody targeting ANGPTL4 designed to lower triglycerides and improve metabolic function SOUTH SAN FRANCISCO and LIBERTY CORNER, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc.

Combined company to focus on developing first-in-class next-generation medicines for cardioendocrine diseases Marea has multiple late-stage clinical product candidates: MAR001/005 for severe hypertriglyceridemia (sHTG) currently in Phase 2b and MAR002 for the treatment of acromegaly which is

Lisata has filed suit against Kuva Labs Inc. and its subsidiary seeking, among other things, damages for the benefit of its stockholders Lisata’s Board of Directors and management continues to evaluate strategic alternatives to enhance stockholder value In order to reduce operating expenses and

Lisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent value right, which represents the contractual right to receive two contingent cash payments of up to an aggregate of $3.00 per share, subject to achievement of specified milestones The transaction

Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share Board of directors unanimously approved the transaction and recommends that stockholders tender their shares Transaction expected